オプションチェーンは、Ginkgo Bioworks Holdingsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Ginkgo Bioworks Holdingsの市場センチメントを評価します。.

Ginkgo Bioworks Holdings (NYSE:DNA) 株価情報, オプションチェーン

Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services.

Ginkgo Bioworks Holdings, Inc. Class A Common Stock

Ginkgo Bioworks Holdings Inc

Metaverse Dualchain Network Architecture

DeNA Co Ltd

DNAPRINT GENOMICS INC by DNAPrint Genomics, Inc.

DNA Print Genomics Inc

DNA Brands Inc

News

Contracts

ConocoPhillips Expects Most Of $2B Divestiture To Occur In 2025

JP Morgan analyst Anupam Rama maintains ORIC Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIC#NASDAQ">ORIC</a>) with a Overweight and raises the price target from $19 to $21.

Price Target

Analyst Ratings

ORIC

JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Raises Price Target to $21

Glen Burnie Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBZ#NASDAQ">GLBZ</a>) reported quarterly losses of $(0.01) per share. This is a 116.67 percent decrease over earnings of $0.06 per share from the same period last year.

Earnings

GLBZ

Glen Burnie Bancorp Q4 EPS $(0.01) Down From $0.06 YoY

Goldman Sachs analyst Brian Lee maintains Mueller Water Products (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MWA#NYSE">MWA</a>) with a Neutral and raises the price target from $26 to $29.

Goldman Sachs Maintains Neutral on Mueller Water Products, Raises Price Target to $29

Lytus Healthcare launched to transform patient care in India
Company positioned to build on revenue growth momentum
Secures strategic financing to fuel next-generation technology expansion
Mumbai, India, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Lytus Technologies Holdings, Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYT#NASDAQ">LYT</a>), a leader in platform services and next-generation technology, is strengthening its position in the high-growth HealthTech sector through Lytus Healthcare, its fully owned subsidiary that is dedicated to revolutionizing patient care and healthcare accessibility in India.
With India's healthcare sector projected to grow at a 22% CAGR, Lytus Healthcare aims to bridge critical gaps in service delivery by integrating AI-driven patient management solutions with personalized, technology-enabled care pathways. The initiative aligns with Lytus' broader strategy of leveraging digital innovation to enhance essential services across its growing subscriber base of over 4 million users.
Building Momentum through Strategic Expansion
Lytus recently reported 26% revenue growth for the first half of FY2025, reflecting increased adoption of its digital platform services and strategic expansion efforts. The company continues to strengthen its portfolio across fintech, AI, and digital services while exploring new markets and revenue streams.
"Our strong revenue growth is a testament to Lytus' ability to execute on its vision and seize market opportunities," added Pandya. "We are committed to sustainable growth while investing in next-generation solutions that enhance both customer experience and shareholder value."
Strategic Financing to Support Expansion
To support its expansion initiatives, Lytus has entered into a Standby Equity Purchase Agreement (SEPA). Under this agreement, Lytus has access up to $100 million to deploy in its businesses as growth capital over the next three years.
An initial $6 million in funding has already been secured under the SEPA, providing Lytus with the flexibility to scale operations, expand its digital ecosystem, and advance HealthTech innovations.
"This financing enhances our ability to invest in high-growth sectors while maintaining operational agility," Pandya noted. "As we build on our technology-driven approach, we remain focused on creating long-term value for our shareholders and stakeholders."

Biotech

Global

General

Lytus Healthcare Launched To Transform Patient Care In India; Reports 26% Revenue Growth In H1 FY2025; Secures $6M Funding Under $100M SEPA To Deploy In Its Businesses As Growth Capital Over The Next 3-Years For Strategic Growth In HealthTech And Digital Services.

Benchmark analyst David Williams maintains Alpha &amp; Omega (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOSL#NASDAQ">AOSL</a>) with a Buy and raises the price target from $40 to $42.

AOSL

Benchmark Maintains Buy on Alpha & Omega, Raises Price Target to $42

JP Morgan analyst Doug Anmuth maintains Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) with a Overweight and lowers the price target from $95 to $90.

UBER

JP Morgan Maintains Overweight on Uber Technologies, Lowers Price Target to $90

Goldman Sachs analyst Leah Jordan maintains Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) with a Buy and lowers the price target from $68 to $60.

MDLZ

Goldman Sachs Maintains Buy on Mondelez International, Lowers Price Target to $60

Goldman Sachs analyst James Yaro maintains Moelis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MC#NYSE">MC</a>) with a Neutral and raises the price target from $79 to $87.

Goldman Sachs Maintains Neutral on Moelis, Raises Price Target to $87

JP Morgan analyst Stephen Tusa maintains Johnson Controls Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>) with a Overweight and raises the price target from $87 to $100.

JP Morgan Maintains Overweight on Johnson Controls Intl, Raises Price Target to $100

Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $72 price target.

Reiteration

CYTK

Needham Reiterates Buy on Cytokinetics, Maintains $72 Price Target

Goldman Sachs analyst Toshiya Hari maintains Impinj (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) with a Neutral and lowers the price target from $200 to $132.

Goldman Sachs Maintains Neutral on Impinj, Lowers Price Target to $132

JP Morgan analyst Alexei Gogolev maintains GoDaddy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDDY#NYSE">GDDY</a>) with a Overweight and raises the price target from $224 to $231.

GDDY

JP Morgan Maintains Overweight on GoDaddy, Raises Price Target to $231

Goldman Sachs analyst Christine Cho maintains Cheesecake Factory (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>) with a Buy and raises the price target from $56 to $64.

CAKE

Goldman Sachs Maintains Buy on Cheesecake Factory, Raises Price Target to $64

Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>) with a Buy and maintains $11 price target.

RXRX

Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target

JP Morgan analyst Mark Strouse upgrades Altus Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>) from Underweight to Neutral and announces $5 price target.

Upgrades

AMPS

JP Morgan Upgrades Altus Power to Neutral, Announces $5 Price Target

Benchmark analyst Cody Acree reiterates ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) from Hold to Hold.

Benchmark Reiterates Hold on ARM Holdingsto Hold

Raymond James analyst Steven Seedhouse maintains Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) with a Strong Buy and raises the price target from $122 to $125.

VKTX

Raymond James Maintains Strong Buy on Viking Therapeutics, Raises Price Target to $125

Needham analyst David Saxon reiterates Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) from Hold to Hold.

GMED

Needham Reiterates Hold on Globus Medicalto Hold

Raymond James analyst Melissa Fairbanks reiterates SiTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SITM#NASDAQ">SITM</a>) with a Outperform and raises the price target from $215 to $250.

SITM

Raymond James Reiterates Outperform on SiTime, Raises Price Target to $250

Ginkgo Bioworks (DNA) is down -8.3%, or -85c to $9.47. Published first on TheFly – the ultimate source for real-time, market-moving breaking financ...

Ginkgo Bioworks falls -8.3%

Ginkgo Bioworks eligible for $9.4M in partnership for bioelectronic devices

Ginkgo Bioworks (DNA) is down -7.7%, or -78c to $9.30. Published first on TheFly – the ultimate source for real-time, market-moving breaking financ...

Ginkgo Bioworks falls -7.7%

Latest data shows the largest indicative borrow rate increases among liquid option names include: Aptiv (APTV) 54.26% +52.03, Nikola (NKLA) 147.81%...

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Mesoblast (MESO) 535.67% +298.96, Aptiv (APTV) 54...

Moderna spikes as Oracle's Larry Ellison touts AI-driven mRNA vaccines

TD Cowen analyst Brendan Smith raised the firm's price target on Ginkgo Bioworks (DNA) to $16 from $10 and keeps a Buy rating on the shares. The fi...

Ginkgo Bioworks price target raised to $16 from $10 at TD Cowen

Stargate Project's healthcare winners: AI-led biotechs and Metagenomi

Latest data shows the largest indicative borrow rate increases among liquid option names include: Beyond Meat (BYND) 53.54% +7.04, Sellas Life Scie...

Ginkgo Bioworks: Declining Core Revenue And High Cash Burn Echo Amyris' Path

ABCL

ABSI

AISP

AMPX

APTV

AZUL

BSGM

BYND

CADL

CHPT

GOEV

HNST

KULR

MEOBF

MESO

MRNA

NKLA

ORCL

QBTS

RCAT

SDGR

TNYA

TSEM

WIMI

Press Releases

NOVUS Leverages Ginkgo Bioworks to Develop Innovative Feed Additives for Animal Agriculture

Finding Family DNA Podcast Series Wins Gold!

Commodities

Ginkgo Bioworks Announces Date of Third Quarter 2024 Results Presentation

Ginkgo Bioworks Advances Collaboration with Merck to Improve Biologics Manufacturing

Ginkgo Bioworks Reports Third Quarter 2024 Financial Results

Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program

Ginkgo Bioworks Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference

Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors

Ginkgo Automation to Deploy Flexible Laboratory Automation System for Cutting-Edge Biofuels and Bioproducts Research at Great Lakes Bioenergy Research Center (GLBRC)

Comments

Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings (DNA) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル